Cargando…
Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
Selexipag is an oral prostacyclin receptor agonist; it was recently approved for use in adults with pulmonary arterial hypertension. The safety and efficacy of selexipag has not yet been determined in the pediatric population. We describe short-term hemodynamic and clinical data with selexipag thera...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026823/ https://www.ncbi.nlm.nih.gov/pubmed/32110381 http://dx.doi.org/10.1177/2045894019876545 |